



Published in final edited form as:

Science. 2008 August 8; 321(5890): 839–843. doi:10.1126/science.1156121.

## Human *CHN1* mutations hyperactivate $\alpha 2$ -chimaerin and cause Duane's retraction syndrome

Noriko Miyake<sup>1,2</sup>, John Chilton<sup>3,\*\*</sup>, Maria Psatha<sup>4,\*\*</sup>, Long Cheng<sup>1,2</sup>, Caroline Andrews<sup>1,2,5</sup>, Wai-Man Chan<sup>1</sup>, Krystal Law<sup>1,+</sup>, Moira Crosier<sup>6</sup>, Susan Lindsay<sup>6</sup>, Michelle Cheung<sup>4</sup>, James Allen<sup>3</sup>, Nick J Gutowski<sup>7,9</sup>, Sian Ellard<sup>8,9</sup>, Elizabeth Young<sup>9</sup>, Alessandro Iannaccone<sup>10</sup>, Binoy Appukuttan<sup>11</sup>, J. Timothy Stout<sup>11</sup>, Stephen Christiansen<sup>12</sup>, Maria Laura Ciccarelli<sup>13</sup>, Alfonso Baldi<sup>14</sup>, Mara Campioni<sup>14</sup>, Juan C. Zenteno<sup>15</sup>, Dominic Davenport<sup>4</sup>, Laura E. Mariani<sup>5</sup>, Mustafa Sahin<sup>2,5</sup>, Sarah Guthrie<sup>4</sup>, and Elizabeth C. Engle<sup>1,2,5,16,17,\*</sup>

<sup>1</sup>Department of Medicine (Genetics), Children's Hospital Boston, Boston, MA 02115, USA

<sup>5</sup>Department of Neurology, Children's Hospital Boston, Boston, MA 02115, USA

<sup>16</sup>Department of Ophthalmology, Children's Hospital Boston, Boston, MA 02115, USA

<sup>2</sup>Harvard Medical School, Boston, MA 02115, USA

<sup>3</sup>Institute of Biomedical and Clinical Science, Peninsula Medical School, Research Way, Plymouth PL6 8BU, UK

<sup>4</sup>MRC Centre for Developmental Neurobiology, King's College, Guy's Campus, London SE1 1UL, UK

<sup>6</sup>MRC-Wellcome Trust Human Developmental Biology Resource (Newcastle), Institute of Human Genetics, Newcastle University, International Centre for Life, Newcastle upon Tyne, NE1 3BZ, UK

<sup>7</sup>Department of Neurology, Royal Devon and Exeter Hospital, Barrack Road, Exeter, Devon, EX2 5DW, UK

<sup>8</sup>Department of Molecular Genetics, Royal Devon and Exeter Hospital, Barrack Road, Exeter, Devon, EX2 5DW, UK

<sup>9</sup>Peninsula Medical School, Barrack Road, Exeter EX2 5DW, UK

\*Corresponding author: Elizabeth C Engle MD, Enders 560.2, Children's Hospital Boston, 300 Longwood Ave, Boston, MA 02115. Tel. 617-919-4030 or 617-919-4759. E-mail: Elizabeth.engle@childrens.harvard.edu.

\*\*These authors contributed equally to the manuscript.

+Deceased.

Genbank Accession numbers

Human *CHN1* mRNA; NMα001822

Mouse *CHN1* mRNA; NMα001113246

Chick *CHN1* mRNA; NMα001012952

Human  $\alpha 2$ -chimaerin protein sequence; NPα001813

Protein data Bank ID

Human  $\alpha 2$ -chimaerin protein sequence; 1XA6

Web sites

UCSC Genome Browser [<http://genome.ucsc.edu/cgi-bin/hgGateway>]

NCBI SNP databases [<http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp>], JSNP database [<http://snp.ims.u-tokyo.ac.jp/index.html>] a

HapMap project [<http://www.hapmap.org/index.html.en>]

HDBR gene expression service [<http://www.hdb.org/>]

Protein Data Bank [<http://www.rcsb.org/pdb/home/home.do>]

MOLMOL [<http://hugin.ethz.ch/wuthrich/software/molmol/>]

Scion Image [<http://www.scioncorp.com/>]

Graphpad Prism 5 for Mac OS X Software v. 5.0a [[www.graphpad.com](http://www.graphpad.com)]

10University of Tennessee Health Science Center, Hamilton Eye Institute, 930 Madison Avenue, Suite 731, Memphis, TN 38163, USA

11Casey Eye Institute, Oregon Health and Science University, 3375 SW Terwilliger Blvd, Portland, OR 97239, USA

12Department of Ophthalmology, University of Minnesota, MMC 493, 420 Delaware St, SE, Minneapolis, MN 55455-0501, USA

13 Fatebenefratelli Hospital, Division of Ophthalmology, Isola Tiberina, Rome, Italy

14Department of Biochemistry 'F. Cedrangolo', Section of Pathologic Anatomy, Second University of Naples, Naples, Italy

15Department of Genetics and Research Unit, Institute of Ophthalmology "Conde de Valenciana", Mexico City, Mexico

17 Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA

## Abstract

The RacGAP molecule  $\alpha 2$ -chimaerin is implicated in neuronal signaling pathways required for precise guidance of developing corticospinal axons. We now demonstrate that a variant of Duane's retraction syndrome, a congenital eye movement disorder in which affected individuals show aberrant development of axon projections to the extraocular muscles, can result from gain-of-function heterozygous missense mutations in *CHNI* that increase  $\alpha 2$ -chimaerin RacGAP activity *in vitro*. A subset of mutations enhances  $\alpha 2$ -chimaerin membrane translocation and/or  $\alpha 2$ -chimaerin's previously unrecognized ability to form a complex with itself. *In ovo* expression of mutant *CHNI* alters the development of ocular motor axons. These data demonstrate that human *CHNI* mutations can hyperactivate  $\alpha 2$ -chimaerin and result in aberrant cranial motor neuron development.

Ocular motility and binocular vision depend on the precise innervation of six extraocular muscles by the oculomotor, trochlear and abducens cranial motor neurons (fig S1A) (1). Disruptions in these developmental processes can cause complex congenital eye movement disorders (2,3), the most common of which is Duane's retraction syndrome (DRS) with an incidence in the general population of approximately 0.1%. Individuals with DRS have restricted abduction and in some cases adduction of their eyes, with retraction of the globe on attempted adduction. Postmortem studies of sporadic DRS revealed absence of the abducens motor neurons and cranial nerve, with anomalous innervation of its target, the lateral rectus muscle, by a branch of the oculomotor nerve (fig. S1B) (4,5).

Four pedigrees (IJ, UA, JH, FY, figs. S1D) segregating a DRS variant as a dominant trait are reported to map to the DURS2 locus on chromosome 2q31 (6–8). Examinations of affected family members established that, while some have a phenotype indistinguishable from sporadic DRS, overall they have a higher incidence of bilateral involvement and of vertical movement abnormalities (8–10) (Fig. 1A). Consistent with these clinical findings, our magnetic resonance (MR) imaging of members of pedigrees FY and JH revealed that, in addition to absent or hypoplastic abducens nerves and aberrant lateral rectus innervation by the oculomotor nerve, some individuals had hypoplastic oculomotor nerves and small oculomotor-innervated muscles (10). Thus, mutations in the DURS2 gene appear to affect primary development of the abducens and, to a lesser degree, the oculomotor nerve (fig. S1C).

To identify the DURS2 gene, we further analyzed the recombination events that defined the published DURS2 critical region (6,7) reducing it from 9.9 to 4.6 Mb (figs. S2A&B), and then sequenced 22 positional candidate genes (fig. S2B) in a proband from each of the four published pedigrees. We identified in each a unique heterozygous missense change in *CHNI*, which

encodes two Rac-specific GTPase-activating  $\alpha$ -chimaerin isoforms. We then screened 16 smaller pedigrees that segregated DRS in a dominant fashion, and identified three additional heterozygous *CHN1* missense changes in pedigrees RF, IS, and AB (Fig. 1B, figs. S1E, S2C). All seven nucleotide substitutions co-segregate with the affected haplotypes and none were present in on-line SNP databases or on 788 control chromosomes. Five of the substitutions are predicted to result in nonconservative (L20F, Y143H, G228S, P252Q, E313K) and two in conservative (I126M, A223V) amino acid substitutions (Fig. 1B). All are predicted to alter amino acids that are conserved in eight different species (fig. S2D).

The Rho family member Rac is a GTPase that is active when GTP-bound, and serves as a regulator of downstream intracellular signaling cascades controlling cytoskeleton dynamics, including the growth and development of dendrites and axons. Rac is inactivated by twelve Rac GTPase activating proteins (GAPs) in the mammalian genome (11), including  $\alpha$ 1- and  $\alpha$ 2-chimaerin encoded by *CHN1*, and paralogs  $\beta$ 1- and  $\beta$ 2-chimaerin encoded by *CHN2*. In rodent brain,  $\alpha$ 2-chimaerin has been shown to serve as an effector for axon guidance (12–16), while  $\alpha$ 1-chimaerin appears to play a later role in dendritic pruning (17,18).

*CHN1* is alternatively spliced, and the  $\alpha$ 1-chimaerin promoter lies in intronic sequence upstream of  $\alpha$ 2-chimaerin exon 7 (19). Thus, the two isoforms share a RacGAP domain that interacts with and down-regulates Rac activity, and a C1 domain that binds to diacylglycerol (DAG), a membrane associated phorbol ester signaling lipid. Only  $\alpha$ 2-chimaerin contains an N-terminal SH2 domain (20,21). Three DURS2 mutations alter amino acids unique to  $\alpha$ 2-chimaerin, while four alter residues shared by  $\alpha$ 1- and  $\alpha$ 2-chimaerin (Fig. 1C, table S1). Because we cannot distinguish between the two groups clinically, the DURS2 phenotype most likely results from altered  $\alpha$ 2-chimaerin function.

*In situ* studies in rat (20,21) revealed widespread embryonic neuronal expression of  $\alpha$ 2-chimaerin mRNA. Expression in the caudal brainstem and cephalic flexure peaked at E12.5, while we found that mouse embryonic expression peaked overall at E10.5 (fig. S3A&B), both consistent with expression of  $\alpha$ 2-chimaerin in developing ocular motor neurons. We found similar widespread expression of  $\alpha$ 2-chimaerin mRNA during human development, strongest at CS15 and CS16 in the midbrain and hindbrain (Fig. 2, fig. S3C–E, S4). Therefore, although expressed in developing ocular motor neurons, the expression pattern alone does not account for the striking restriction of the DURS2 phenotype.

All seven amino acids altered by DURS2 mutations are conserved in  $\alpha$ 2-chimaerin's paralog,  $\beta$ 2-chimaerin (fig. S5A&B). Both molecules are predicted to exist in inactive, closed conformations in the cytoplasm, and to unfold and translocate to the membrane in response to DAG signaling, exposing their RacGAP domains and inactivating Rac (12, 22).  $\beta$ 2-chimaerin crystallization revealed that its inactive conformation is maintained by intramolecular interactions that impede access to the Rac and DAG binding sites (22). Modeling the DURS2 mutations onto the  $\beta$ 2-chimaerin structure (fig. S5C–E) (22) leads to several predictions: 1)  $\alpha$ 2-chimaerin L20 and I126 correspond to two of nine residues predicted by Canagarajah *et al* to stabilize the  $\beta$ 2-chimaerin closed conformation and, when mutated to alanine, were shown to enhance  $\beta$ 2-chimaerin translocation to the membrane *in vitro*; 2) Y143 is predicted to interact with Y221, while A223 is adjacent to N224 that is predicted to interact with Y133, and altering either of these residues may also destabilize the  $\alpha$ 2-chimaerin closed conformation; 3)  $\alpha$ 2-chimaerin G228 is the predicted DAG binding site; 4) E313 is adjacent to the predicted Rac binding site. These predictions led us to hypothesize that DURS2 mutations hyper-activate  $\alpha$ 2-chimaerin RacGAP activity by destabilizing its closed conformation, or by directly altering DAG or Rac binding.

To determine whether DURS2 mutations alter the RacGAP activity of  $\alpha 2$ -chimaerin, we made full-length wild-type and mutant  $\alpha 2$ -chimaerin constructs that expressed equally stable proteins in HEK293T cells and primary neurons (Fig. 3, fig. S6A). Consistent with  $\alpha 2$ -chimaerin function, wild-type overexpression resulted in a reduction in Rac-GTP levels from baseline in HEK293T cells (Fig 3A). As predicted, overexpression of each mutant  $\alpha 2$ -chimaerin protein resulted in a significant further reduction in Rac-GTP levels when compared to wild-type protein (Fig. 3A&B), including when both wild-type and L20F- $\alpha 2$ -chimaerin were co-expressed together in the presence of the DAG analog, phorbol myristoyl acetate (PMA) (fig. S6B&C). We conclude that all seven DURS2 mutations behave as dominant gain-of-function alleles (these and other data for each mutation are summarized in table S1).

Next, we quantified the amount of wild-type and mutant  $\alpha 2$ -chimaerin translocated to the HEK293T cell membrane prior to and after stimulation with PMA. Approximately 15% of wild-type- $\alpha 2$ -chimaerin but a significantly greater fraction of L20F-, Y143H-, A223V-, and P252Q- $\alpha 2$ -chimaerin mutant proteins translocated to the membrane fraction in a PMA dose-dependent manner (Fig. 3C&D, fig. S6D&E). Thus, these four mutant residues appear to enhance membrane translocation and RacGAP activity by destabilizing the closed conformation of  $\alpha 2$ -chimaerin in response to PMA.

Individuals with DURS2-DRS harbor one mutant and one wild-type *CHN1* allele. Therefore, we performed co-immunoprecipitation experiments to ask if mutant hyper-activated  $\alpha 2$ -chimaerin could interact with the wild-type protein, thus potentially recruiting the wild-type pool to the membrane and further reducing Rac activity *in vivo*.  $\alpha 2$ -chimaerin and each of the seven mutants were precipitated minimally by wild-type  $\alpha 2$ -chimaerin in the absence of PMA, and to a much greater extent in its presence, suggesting that  $\alpha 2$ -chimaerin can complex with itself in a manner partially dependent on the PMA dose (Fig. 3E&F, fig. S6F). In addition, in the presence of PMA, the interaction of wild-type- $\alpha 2$ -chimaerin with all mutants except G228S and E313K was significantly enhanced compared to its interaction with itself (Fig. 3F). Neither wild-type- nor L20F- $\alpha 2$ -chimaerin co-immunoprecipitated with  $\alpha 1$ -chimaerin (fig. S6G), supporting a direct or indirect association of  $\alpha 2$ -chimaerin with itself that may involve its SH2 domain.

Based on our findings that DURS2 mutations hyper-activate  $\alpha 2$ -chimaerin, we hypothesized that over-expressing  $\alpha 2$ -chimaerin may result in aberrant axon development *in vivo*. To test this, we used the chick *in ovo* system to over-express  $\alpha 2$ -chimaerin in the embryonic oculomotor nucleus. This nucleus is more amenable to electroporation than the abducens, its development in chick has been defined (23), and we previously demonstrated that some DURS2-DRS individuals have clinical and MR findings supporting a primary defect in oculomotor nerve development (8–10). Similar to rodent and human, chick  $\alpha 2$ -chimaerin mRNA is expressed in neuroepithelia at stages of cranial motor neuron development (E4), and specifically in the developing oculomotor nucleus at the stage of axon extension and branching (E6) (Fig. 4A&B). We electroporated embryonic chick midbrains with GFP-tagged wild-type and mutant- $\alpha 2$ -chimaerin (L20F and G228S) and GFP-alone control constructs at E2. These were analyzed between E5.5 (fig. S7), when oculomotor axons have extended along an unbranched trajectory to their distal target, the ventral oblique muscle (VO), and E6, when branching to the other target muscles has ensued (Fig. 4C–I) (23). All eighteen GFP control embryos showed a normal projection pattern in which the oculomotor nerve reached the ventral oblique muscle and branched correctly into other target muscles by E6 (Fig. 4D) (23). In the majority (71–87%) of embryos over-expressing wild-type or mutant construct, the oculomotor nerve stalled and its axons terminated prematurely adjacent to the dorsal rectus muscle (Fig. 4G–I). In addition, 67% of mutant, while only 24% of wild-type overexpressing embryos, displayed aberrant branching and/or defasciculation of the oculomotor nerve (Fig. 4F, fig. S7A–H). Regardless of the construct we used, the electroporated oculomotor nucleus appeared

normal in size and neuron cell bodies displayed normal sorting, including normal migration across the midline (fig. S7 I&J) (23), consistent with a primary defect in axon rather than cell body development. Taken together, these observations suggest that elevated RacGAP activity as a result of hyperactivated mutant or over-expressed wild-type  $\alpha 2$ -chimaerin results in deregulation of normal oculomotor axon development.

Eph receptors and ephrins (24), and neuropilin receptors and semaphorins (25) are expressed in developing cranial motor nuclei in chick and/or rodent. Several recent papers report that  $\alpha 2$ -chimaerin interacts with the EphA4 receptor and inactivates Rac in response to ephrin/EphA4 signaling (13–16). Loss of  $\alpha 2$ -chimaerin impairs EphA4 forward signaling *in vivo* and eliminates ephrin-induced growth cone collapse *in vitro* (13–16).  $\alpha 2$ -chimaerin has also been implicated in semaphorin3A-induced growth cone collapse (12). EphA4 receptor stimulation can recruit and activate phospholipase C $\gamma$ 1, elevating DAG levels (26). Therefore, mutant  $\alpha 2$ -chimaerin may be hyperactivated in response to a chemorepellant such as ephrins or semaphorins, resulting in pathological inactivation of Rac and altered transduction of downstream signals (S8A–C).

Mice with loss of  $\alpha 2$ -chimaerin have disrupted ephrin/EphA4 signaling and elevated RacGTP levels, with a phenotype limited to a hopping rabbit-like gait resulting from excessive and aberrant midline crossing of corticospinal tract axons and spinal interneuron projections, with no cranial nerve defects reported (13–15). We have now identified human  $\alpha 2$ -chimaerin mutations that enhance its function, reduce RacGTP levels, and result in an ocular motor phenotype resulting from errors in cranial motor neuron development. It is remarkable that the up- and down-regulation of such a widely expressed signaling molecule results in two restricted and apparently non-overlapping phenotypes. It remains to be determined in which signaling pathways  $\alpha 2$ -chimaerin functions in corticospinal and cranial motor axons and why these different motor circuits are uniquely vulnerable to different perturbations in RhoGTPase activity.


## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## References and Notes


1. Supplemental figures and materials and methods are available as supporting material on *Science* Online.
2. Engle EC. Archives of Neurology May;2007 64:633. [PubMed: 17502461]
3. Jen J, et al. Neurology Aug 13;2002 59:432. [PubMed: 12177379]
4. Hotchkiss MG, Miller NR, Clark AW, Green WG. Archives of Ophthalmology May;1980 98:870. [PubMed: 7378011]
5. Miller NR, Kiel SM, Green WR, Clark AW. Archives of Ophthalmology Sep;1982 100:1468. [PubMed: 7115176]
6. Appukuttan B, et al. American Journal of Human Genetics 1999;65:1639. [PubMed: 10577917]
7. Evans JC, Frayling TM, Ellard S, Gutowski NJ. Human Genetics 2000;106:636. [PubMed: 10942112]
8. Engle EC, Andrews C, Law K, Demer JL. Investigative Ophthalmology and Visual Science Jan;2007 48:189. [PubMed: 17197532]
9. Chung M, Stout JT, Borchert MS. Ophthalmology 2000;107:500. [PubMed: 10711888]
10. Demer JL, Clark RA, Lim KH, Engle EC. Investigative Ophthalmology and Visual Science Jan;2007 48:194. [PubMed: 17197533]
11. Dalva MB. Neuron Sep 6;2007 55:681. [PubMed: 17785174]
12. Brown M, et al. Journal of Neuroscience Oct 13;2004 24:8994. [PubMed: 15483118]
13. Iwasato T, et al. Cell Aug 24;2007 130:742. [PubMed: 17719550]
14. Wegmeyer H, et al. Neuron Sep 6;2007 55:756. [PubMed: 17785182]

15. Beg AA, Sommer JE, Martin JH, Scheiffele P. *Neuron* Sep 6;2007 55:768. [PubMed: 17785183]
16. Shi L, et al. *Proceedings of the National Academy of Sciences of the United States of America* Oct 9;2007 104:16347. [PubMed: 17911252]
17. Van de Ven TJ, VanDongen HM, VanDongen AM. *Journal of Neuroscience* Oct 12;2005 25:9488. [PubMed: 16221859]
18. Buttery P, et al. *Proceedings of the National Academy of Sciences of the United States of America* Feb 7;2006 103:1924. [PubMed: 16446429]
19. Dong JM, Smith P, Hall C, Lim L. *European Journal of Biochemistry* Feb 1;1995 227:636. [PubMed: 7867622]
20. Hall C, et al. *Molecular and Cellular Biology* Aug;1993 13:4986. [PubMed: 8336731]
21. Hall C, et al. *Journal of Neuroscience* Jul 15;2001 21:5191. [PubMed: 11438594]
22. Canagarajah B, et al. *Cell* Oct 29;2004 119:407. [PubMed: 15507211]
23. Chilton JK, Guthrie S. *Journal of Comparative Neurology* May 3;2004 472:308. [PubMed: 15065126]
24. Cooke JE, Moens CB. *Trends in Neurosciences* May;2002 25:260. [PubMed: 11972963]
25. Guthrie S. *Nat Rev Neurosci* Nov;2007 8:859. [PubMed: 17948031]
26. Zhou L, et al. *Journal of Neuroscience* May 9;2007 27:5127. [PubMed: 17494698]
27. Sahin M, et al. *Neuron* Apr 21;2005 46:191. [PubMed: 15848799]
28. We dedicate this paper to the memory of Krystal Law, who researched DURS2 in the Engle lab for her undergraduate thesis at Harvard University. We thank the families for their participation, members of the Engle lab for their thoughtful comments, Joseph Demer for pedigree referral, and Matt Gregas, Alessia Di Nardo, Yuko Harada, and Iris Eisenberg for technical advice or assistance. This work was supported in part by grants from the National Eye Institute [ECE], the Children's Hospital Boston Mental Retardation and Developmental Disabilities Research Center [ECE and MS], the Spinal Muscular Atrophy Foundation and American Academy of Neurology [MS], South West Regional Development Agency (UK) [JC, JA], Wellcome Trust [MC, NJG, SG, SL, MP and EY], Medical Research Council (UK) [MC, SG, SL], Clayton Foundation for Research [JTS and BA], Research to Prevent Blindness, Inc [JTS, BA, AI (CDA and unrestricted grant to UTHSC HEI)], and Futura-Onlus, Italy [AB]. ECE is a Howard Hughes Medical Institute Investigator.




**Figure 1. Duane's retraction syndrome (DRS) and corresponding *CHN1* mutations**

(A) Affected member of pedigree JH with limited outward gaze (abduction) and narrowing of the palpebral fissure on attempted inward gaze (adduction) most obvious on leftward gaze. He also has bilateral exotropia on downgaze. (B) The seven DURS2-DRS pedigrees and corresponding heterozygous *CHN1* mutations. (C) Schematic representation of  $\alpha 1$ - (top, 334 amino acids) and  $\alpha 2$ -chimaerin (bottom, 459 amino acids) protein. The isoforms contain identical C1 and RacGAP domains, while only  $\alpha 2$ -chimaerin contains an SH2 domain. Mutations alter residues unique to  $\alpha 2$ -chimaerin or common to both proteins, as indicated by the arrows. No mutations were found in the  $\alpha 1$ -chimaerin N-terminal sequence (highlighted in black).



**Figure 2. Human developmental expression profile of  $\alpha 2$ -chimaerin mRNA by *in situ* hybridization** (A) Transverse section of CS15 human embryo showing  $\alpha 2$ -chimaerin mRNA expression (purple deposit) in midbrain (mb), hindbrain (rhombomere [rh] 2 indicated), spinal cord (sc). (B) Higher magnification of (A) showing expression in the ventricular layer of rh3 and rh4. (C) At CS16 expression is also seen in mb, hindbrain (hb), sc, and vestibulocochlear (viii) and vagus (x) nuclei. Higher magnifications of (C) show (D) expression in developing oculomotor neurons (o) and (E) in neurons of rh5 (developing abducens neurons) and rh6. In CS19 sagittal section (F), expression has declined in basal mb and hb and is now found in dorsal root ganglia (drg), cerebellum (cb), diencephalons (dc), and telencephalon (t). At later stages (G), expression is located in specific regions of the cortical plate (c), intermediate (i) and ventricular zone (v) of the forebrain (11 wpo). No signal was detected in corresponding sections hybridized with sense probe (fig. S4). Scale bars 1000 $\mu$ m (A, C), 100 $\mu$ m (B, E), 200 $\mu$ m (D), 2000 $\mu$ m (F), 500 $\mu$ m (G).






**Figure 3. DURS2-DRS mutations enhance  $\alpha$ 2-chimaerin function *in vitro*.**

(A) Rac-GTP levels were measured in HEK293T cells transfected with plasmids encoding for myc-ephexin, V5-empty vector, V5- $\alpha$ 2-chimaerin wild-type, or V5- $\alpha$ 2-chimaerin mutant. Rac-GTP levels are reduced by overexpression of wild-type  $\alpha$ 2-chimaerin compared to empty vector, and further reduced in cells expressing each mutant, while elevated with overexpression of a GEF, myc-ephexin (27). (B) Densitometric analysis of Rac-GTP levels normalized to total Rac and V5- $\alpha$ 2-chimaerin levels. Values are expressed as percent of wild-type  $\alpha$ 2-chimaerin (mean+SEM, n = 6–10). The difference between the reduction of Rac-GTP levels for each mutant compared to wild-type  $\alpha$ 2-chimaerin is significant by one-way ANOVA with Dunnett's adjustment (F=9.89, \*p<0.03, \*\*p<0.005, \*\*\*p<0.0001). (C)  $\alpha$ 2-chimaerin translocation examined by immunoblots of total, soluble and pellet fraction of wild-type and mutant  $\alpha$ 2-chimaerin +/- 10 PMA stimulation. (D) Graphical representation of translocation following PMA compared to pretreatment expressed as the percent of  $\alpha$ 2-chimaerin remaining in the soluble fraction (mean+SEM, n = 3). Enhanced translocation compared to wild-type is significant for L20F, Y143H, A223V, and P252Q by one-way ANOVA with Dunnett's

adjustment ( $F=21.00$ ,  $*p<0.0001$ ). (E) GFP- $\alpha 2$ -chimaerin immunoprecipitates with V5-wild-type- or V5-L20F- $\alpha 2$ -chimaerin in the presence of PMA, and minimally in its absence. (F) In the presence of PMA, immunoprecipitation of wild-type  $\alpha 2$ -chimaerin is enhanced by all mutant- $\alpha 2$ -chimaerins compared to wild-type except G228S and E313K, which were equivalent to wild-type  $\alpha 2$ -chimaerin. Results were consistent over at least four independent experiments (also see fig. S6F&G).



**Figure 4.  $\alpha 2$ -chimaerin overexpression results in stalling of developing chick oculomotor nerves** (A) Transverse section through E4 whole chick embryo showing wide neuroepithelial expression of  $\alpha 2$ -chimaerin mRNA including the hindbrain (hb), forebrain (fb), and trigeminal ganglion (tg). (B) Transverse section through E5-6 chick midbrain showing  $\alpha 2$ -chimaerin mRNA expression in the oculomotor nuclei (left nucleus circled in white). (C) Tabulated results of electroporated constructs. (D-I) Confocal image montages (white hatches denote image breaks) at E6 of electroporated oculomotor nerves (green) and extraocular muscles (red) labeled with anti-myosin antibody (D,E,G-I) or  $\alpha$ -bungarotoxin (F); constructs as labeled. All GFP-control (D), 28% of wild-type (E), and only 5–13% of mutant  $\alpha 2$ -chimaerin electroporated oculomotor nerves extend normally from the midbrain neuroepithelium, at left, past the dorsal rectus muscle (DR), ciliary ganglion (\*), and ventral (VR) and medial (MR) recti to innervate the first target, the ventral oblique (VO) muscle. Nerves expressing mutant  $\alpha 2$ -chimaerin have a higher incidence of aberrant branching (arrow in F with higher magnification inset) and defasciculation than wildtype (fig. S7). Most remarkably, 72% of wildtype (G), 87% of L20F (H), and 71% of G228S- $\alpha 2$ -chimaerin (I) electroporated nerves stall in the vicinity of the DR muscle. Scale bars are 200  $\mu$ m.